TW201136587A - An agent for enhancing the expression of redox-associated factors - Google Patents
An agent for enhancing the expression of redox-associated factors Download PDFInfo
- Publication number
- TW201136587A TW201136587A TW100103496A TW100103496A TW201136587A TW 201136587 A TW201136587 A TW 201136587A TW 100103496 A TW100103496 A TW 100103496A TW 100103496 A TW100103496 A TW 100103496A TW 201136587 A TW201136587 A TW 201136587A
- Authority
- TW
- Taiwan
- Prior art keywords
- redox
- redox reaction
- related factor
- protein
- extract
- Prior art date
Links
- 230000002708 enhancing effect Effects 0.000 title 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 61
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 58
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 29
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 29
- 235000005875 quercetin Nutrition 0.000 claims abstract description 29
- 229960001285 quercetin Drugs 0.000 claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 28
- 239000009429 Ginkgo biloba extract Substances 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 229930182470 glycoside Natural products 0.000 claims abstract description 7
- 150000002338 glycosides Chemical class 0.000 claims abstract description 7
- 238000006479 redox reaction Methods 0.000 claims description 79
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 102000004169 proteins and genes Human genes 0.000 claims description 40
- 239000003623 enhancer Substances 0.000 claims description 33
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 27
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 23
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 23
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 18
- 239000005864 Sulphur Substances 0.000 claims description 16
- 108010024636 Glutathione Proteins 0.000 claims description 15
- 108090000854 Oxidoreductases Proteins 0.000 claims description 11
- 229960003180 glutathione Drugs 0.000 claims description 11
- 239000011593 sulfur Substances 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 claims description 9
- 108010063907 Glutathione Reductase Proteins 0.000 claims description 8
- 235000016140 Artemisia frigida Nutrition 0.000 claims 1
- 235000000532 Salvia regla Nutrition 0.000 claims 1
- 235000008803 Teucrium scorodonia Nutrition 0.000 claims 1
- 240000008461 Teucrium scorodonia Species 0.000 claims 1
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 abstract description 66
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 abstract description 32
- 235000008777 kaempferol Nutrition 0.000 abstract description 32
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 abstract description 32
- 230000036542 oxidative stress Effects 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000009467 reduction Effects 0.000 abstract description 4
- 241000234305 Hedychium Species 0.000 abstract 1
- 230000036449 good health Effects 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- -1 glutathione free radical Chemical class 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 238000001035 drying Methods 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 13
- 230000001737 promoting effect Effects 0.000 description 13
- 108060008226 thioredoxin Proteins 0.000 description 13
- 102000002933 Thioredoxin Human genes 0.000 description 12
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 12
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 229940094937 thioredoxin Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 102000004316 Oxidoreductases Human genes 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 9
- 150000002216 flavonol derivatives Chemical class 0.000 description 9
- 235000011957 flavonols Nutrition 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 5
- 102000002278 Ribosomal Proteins Human genes 0.000 description 5
- 108010000605 Ribosomal Proteins Proteins 0.000 description 5
- 235000004879 dioscorea Nutrition 0.000 description 5
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 5
- 239000000419 plant extract Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 230000006697 redox regulation Effects 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108050005205 Glutaredoxin Proteins 0.000 description 3
- 102000017278 Glutaredoxin Human genes 0.000 description 3
- 108010053070 Glutathione Disulfide Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- HNURKXXMYARGAY-UHFFFAOYSA-N 2,6-Di-tert-butyl-4-hydroxymethylphenol Chemical compound CC(C)(C)C1=CC(CO)=CC(C(C)(C)C)=C1O HNURKXXMYARGAY-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 244000062241 Kaempferia galanga Species 0.000 description 2
- 235000013421 Kaempferia galanga Nutrition 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 102000007456 Peroxiredoxin Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 2
- 235000007743 myricetin Nutrition 0.000 description 2
- 229940116852 myricetin Drugs 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 108030002458 peroxiredoxin Proteins 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XEFAJZOBODPHBG-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1 XEFAJZOBODPHBG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WLRWTEIAYJHXDW-UHFFFAOYSA-N 2,2,3,3,4,4,4a,5,5,6-decamethyl-6H-cyclopenta[b]pyran Chemical compound CC1C=C2C(C(C(C(O2)(C)C)(C)C)(C)C)(C1(C)C)C WLRWTEIAYJHXDW-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- DDKWZUMWCMLKPW-UHFFFAOYSA-N 2-(4-hydroxyphenoxy)carbonylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)OC1=CC=C(O)C=C1 DDKWZUMWCMLKPW-UHFFFAOYSA-N 0.000 description 1
- 239000004808 2-ethylhexylester Substances 0.000 description 1
- CNXZMGRWEYQCOQ-UHFFFAOYSA-N 2-methoxy-3-phenylprop-2-enoic acid Chemical compound COC(C(O)=O)=CC1=CC=CC=C1 CNXZMGRWEYQCOQ-UHFFFAOYSA-N 0.000 description 1
- CVNPKVXQUCOSOI-UHFFFAOYSA-N 3-ethylheptane-2,3-diol Chemical compound CCCCC(O)(CC)C(C)O CVNPKVXQUCOSOI-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- KIBSOJDHBVJPHE-UHFFFAOYSA-N C(CCCCCCCCCCCC)C(C(=O)O)(CCCCCCCC)OCCCCCCCCCC Chemical compound C(CCCCCCCCCCCC)C(C(=O)O)(CCCCCCCC)OCCCCCCCCCC KIBSOJDHBVJPHE-UHFFFAOYSA-N 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- PHFSBARLASYIFM-LDYMZIIASA-N Fukiic acid Chemical compound OC(=O)[C@@H](O)[C@@](O)(C(O)=O)CC1=CC=C(O)C(O)=C1 PHFSBARLASYIFM-LDYMZIIASA-N 0.000 description 1
- PHFSBARLASYIFM-UHFFFAOYSA-N Fukiic-Saeure Natural products OC(=O)C(O)C(O)(C(O)=O)CC1=CC=C(O)C(O)=C1 PHFSBARLASYIFM-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102100025945 Glutaredoxin-1 Human genes 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 101000845013 Homo sapiens Thioredoxin reductase 2, mitochondrial Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 101710166307 Protein lines Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000061457 Solanum nigrum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 102000002932 Thiolase Human genes 0.000 description 1
- 108060008225 Thiolase Proteins 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 description 1
- 240000003243 Thuja occidentalis Species 0.000 description 1
- 235000008109 Thuja occidentalis Nutrition 0.000 description 1
- 244000044283 Toxicodendron succedaneum Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- MXJDHESCSJVNQP-UHFFFAOYSA-N [Na].CC#N Chemical compound [Na].CC#N MXJDHESCSJVNQP-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- UTMTYYKGLQURCK-UHFFFAOYSA-N butane-1,3-diol;propane-1,2,3-triol Chemical compound CC(O)CCO.OCC(O)CO UTMTYYKGLQURCK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 208000030632 cutaneous sclerosis Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NXZJVGJFARZKDK-UHFFFAOYSA-N didecyl(dioctadecyl)azanium Chemical compound C(CCCCCCCCCCCCCCCCC)[N+](CCCCCCCCCC)(CCCCCCCCCC)CCCCCCCCCCCCCCCCCC NXZJVGJFARZKDK-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 150000002214 flavonoid derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010807 real-time PCR kit Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000025078 regulation of biosynthetic process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229920001959 vinylidene polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940119569 wormwood extract Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
Description
201136587 六、發明說明: 【發明所屬之技術領域】 本發明係關於一種含有山奈酚、槲皮素或該等之糖苷、 或该等之組合作為有效成分而成的氧化還原反應相關因子 表現促進劑,以及含有銀杏葉萃取物、山奈萃取物或該等 / 之組合作為有效成分而成的氧化還原反應相關因子表現促 . 進劑。 【先前技術】 生物體為維持自身生存,維持恆常性而進行氧化還原調 節。生物體内之氧化還原調節主要基於細胞内之蛋白質中 所存在的半胱胺酸殘基上之硫醇基之可逆氧化還原反應, 而控制各種細胞功能。已知氧化還原調節相關因子(氧化還 原反應相關因子)使細胞内保持還原狀態,發揮對細胞之生 存而έ必需之作用,另一方面,對生物體内之活性氧種之 消去亦發揮重要之作用。於上述氧化還原反應相關因子未 正常發揮功能之情形時,生物體内之活性氧種產生過剩, 而承受過度之氧化壓力。一般認為,上述過度之氧化壓力 • 將DNA、蛋白f、脂質之生物體高分子氧化而對該等造成 • 傷害,從而導致各種疾病或老化。因此,近年來,盛行研 - 冑作為導致氧化麗力之活性氧種之消去系統而發揮作用的 氧化還原反應相關因子。 作為應對生物體之氧化壓力之防禦機構而發揮作用的氧 化還原反應相關因子已知有麩胱普肽系。 j 1曰扣·缝 1肽為存在於哺乳動物體内之三肽,具有利用分 * *9之 153851.doc 201136587 硫醇基之還原仙、作為制之仙、參與賴尿酸之生 成及其他解毒機構之作用、保護硫醇酶或其他細胞成分之 作用、促進有害物排泄之作用、由提高膽㈣酶之活性而 產生之抗過敏作用、酶活化作用1而,由於麩胱苦狀於 製劑中產生沈殿’並且大量細胞中無法取得麵胱苦狀,故 用以促進細胞内麩胱苷肽之產生之成分變得極其有用。作 為此種成分,迄今為止報告有γ_生育酚或§_生育酚,並揭示 有含有該等成分之麩胱苷肽產生促進劑(曰本專利特開 2007-284430(專利文獻1)}。 另外,作為其他氧化還原反應相關因子,已知有硫氧化 還原蛋白系,硫氧化還原蛋白系亦作為應對生物體内之氧 化壓力的防禦機構而發揮作用(細胞工程學v〇丨2 5、N〇 2、 2006、P143-148(非專利文獻丨))。另外,有報告指出:硫氧 化還原蛋白之基因轉殖鼠變得長壽(Mhsui A,et &
Antioxid Redox Signal (2002) 4 : 693-696(非專利文獻 2)); 硫氧化還原蛋白對腦梗塞、糖尿病具有抵抗性(Takagi Y,et ah Proc Natl Acad Sci USA (1999) 96..4131-4136(非專利文 獻 3)、Hotta M,et al: J Exp Med (1998) 188·· 1445-145!(非 專利文獻4));以及對過敏性皮炎有效(曰本專利特開 2007-269671(專利文獻2));並且硫氧化還原蛋白廣泛用作 活性氧消去劑(曰本專利特開平9-157153(專利文獻3))。然 而’由於硫氧化還原蛋白系為高分子蛋白質,故即便對對 象直接投予該等化合物’亦無法將該等之分子取入細胞 内。因此’較理想為促進生物體内硫氧化還原蛋白系之表 153851.doc 201136587 現,但促進該等之表現之成分迄今為止僅知有艾草萃取物 及青紫蘇萃取物(國際公開編號W〇 2006/033351 (專利文獻 4))。 如上所述,即便對生物體直接投予麩胱苷肽系或硫氧化 還原蛋白系等氧化還原反應相關因子,亦無法有效地取入 細胞内’故有於生物體内無法發揮氧化還原調節功能或抗 氧化功能之虞。已知藉由紫外線照射壓力可促進該等氧化 還原反應相關因子之表現,但迄今為止幾乎尚未知曉安全 且有效地對生物體發揮作用之化學物質,亦未詳細闡明生 物體内之氧化還原反應相關因子之表現機制。因此,仍然 期待發現一種用以促進生物體内氧化還原反應相關因子之 表現的安全且有效之成分。 [先前技術文獻] [專利文獻] [專利文獻1]日本專利特開2007-284430 [專利文獻2]日本專利特開2007-269671 [專利文獻3]曰本專利特開平9-1 57153 [專利文獻4]國際公開編號WO 2006/033351 [非專利文獻] [非專利文獻1]細胞工程學Vol.25'No.2、2006、pi 43-148 [非專利文獻 2] Mitsui A, et al: Antioxid Redox Signal (2002)4: 693-696 [非專利文獻 3] Takagi Y, et al: Proc Natl Acad Sci USA (1999) 96: 4131-4136 153851.doc 201136587 [非專利文獻 4] Hotta M,et al: J Exp Med (1998) 188: 1445-1451 【發明内容】 [發明所欲解決之問題] 本發明之課題在於藉由促進生物體内氧化還原反應相關 因子之表現,而安全且有效地減少生物體之氧化壓力,維 持健康’並防止由氧化壓力引起之各種疾病及症狀。 [解決問題之技術手段] 本發明者等人此次發現’促進作為生物體内之氧化還原 反應相關因子的麩胱苷肽系及硫氧化還原蛋白系之表現及 活性之成分有屬於黃酮醇類之山奈酚及槲皮素。令人意外 的是’該作用僅對黃酮醇類中之山奈酚與槲皮素具有特異 性’於結構類似之楊梅黃酮令未確認到上述作用。與直接 使用麩胱苷肽系或硫氧化還原蛋白系之分子之情形相比, 使用山奈紛或槲皮素可更有效地促進生物體内之麩胱苷肽 系或硫氧化還原蛋白系等氧化還原反應相關因子之表現及 活性’故而藉由本發明可更有效地減輕生物體内多種多樣 之氧化壓力。山奈酚或槲皮素等黃酮醇類廣泛分佈於茶葉 植物中,對生物體無毒,可安全地攝取。如此般,藉由將 山奈酚及槲皮素作為用以促進生物體内之氧化還原反應相 關因子之表現的有效成分,可不對所使用之生物體賦予壓 力而消去生物體内過剩之活性氧種。 因此,本申請案包含以下發明: [1 ] 一種氧化還原反應相關因子表現促進劑,其係含有 15385 丨.doc 201136587 山奈紛、樹皮素或料之料、或料之組合作為有效成 分而成。 [] 上这[1 ]之乳化還原反應相關因子表現促進劑,其 中上述氧化還原反應相關因子為選自由硫氧化還原蛋白、 硫氧化還原蛋白還原酶'麵胱苷肽還原酶及麩氧還蛋白所 組成之群中之1種或複數種物質。 [] 種氧化還原反應相關因子表現促進劑,其係含有 銀杏葉萃取物、山奈萃取物或該等之組合作為有效成分而 成。 [4] 如上述[3]之氧化還原反應相關因子表現促進劑,其 中上述氧化還原反應相關因子為選自由硫氧化還原蛋白、 硫氧化還原蛋白還原酶、麵胱苷肽還原酶及麩氧還蛋白所 組成之群中之1種或複數種物質。 [5] —種山奈酚、槲皮素或該等之糖苷、或該等之組合 之用途’其係用以製備氧化還原反應相關因子表現促進劑。 [6] —種銀杏葉萃取物、山奈萃取物或該等之組合之用 途’其係用以製備氧化還原反應相關因子表現促進劑。 [發明之效果] 藉由促進生物體内之氧化還原反應相關因子之表現,可 安全且有效地減少生物體内之活性氧種,而防禦生物體免 受氧化壓力之影響。藉此可維持生物體之健康,並可防止 由氧化壓力引起之各種疾病及症狀。 【實施方式】 於本發明之一實施態樣中,提供一種含有山奈酚、槲皮 15385 丨.doc 201136587 素或該等之糖苷、或該等之組合作為有效成分而成的氧化 還原反應相關因子表現促進劑。 於本說明書中’「氧化還原反應相關因子」係指與生物體 例如哺乳類’較佳為人體内所存在的蛋白質中之半胱胺酸 殘基上之硫醇基進行氧化或還原反應,而使細胞内保持還 原狀態之因子。本發明者認為,於細胞之活化或訊息傳遞 物質之處理即訊號傳遞機構中,尤其是由細胞内之蛋白質 中所存在的半胱胺酸殘基上之硫醇基之氧化引起的蛋白質 -蛋白質間相互作用中之修飾發揮重要作用。上述半胱胺酸 殘基上之硫醇基之氧化•還原(redox)參與基因之轉錄,蛋 白質於細胞内之局部存在、合成、分解之調節,及細胞增 殖或細胞死亡等各種生命現象之調節。作為此種生物體内 之氧化還原反應相關物質’已知有麵胱苦肽系及硫氧化還 原蛋白系’該等分別由一群分子所構成。已知該等氧化還 原反應相關因子亦參與產生及存在於生物體内之活性氧種 之消去。 硫氧化還原蛋白系尤其是由硫氧化還原蛋白與硫氧化還 原蛋白還原酶等因子所構成。硫氧化還原蛋白(TRX)係作為 向大腸桿菌之DNA合成所必需之酶即核糖核苷酸還原酶供 應氫之輔酶而被發現。TRX為原核生物或人類之多種生物 體内所保存之約12 kDa之蛋白質,具有包括4個β摺疊與3個 α螺旋之立體結構’且之活性部位。 TRX存在有在其活性部位之2個半胱胺酸殘基間形成雙硫 鍵之氧化型(S-S)、與還原型,SH-),還原型係將基質 153851.doc 201136587 蛋白質之雙硫鍵還原,自身變成氧化型。氧化型trx藉由 NADPH(nicotinamideadeninedinucle〇tide 沖〇_价,終醯 胺腺嘌呤二核苷酸磷酸)與硫氧化還原蛋白還原酶而還 原,再生為還原型。作為基質蛋白質之一種,已知有總稱 為過氧化物氧還蛋白(peroxiredoxin)2H2〇2消去酶家族。還 原型過氧化物氧還蛋白將H2〇2還原。並且,變成氧化型之 過氧化物氧還蛋白成為基質並被硫氧化還原蛋白所還原。 變成氧化型之硫氧化還原蛋白被硫氧化還原蛋白還原酶所 還原。硫氧化還原蛋白系對此種活性氧種之無毒化系統發 揮重要之作用。 麩胱苷肽系尤其是由麩胱苷肽、麵胱苷肽還原酶及麩氧 還蛋白(glutaredoxin)等因子所構成。麩胱苷肽係包含麵胺 酸、半胱胺酸及甘胺酸之三肽,作為非蛋白質性之硫醇成 分大篁存在於細胞内,並作為細胞内之親水性組分中之主 要抗氧化物質而為人所知。麩胱苷肽與活性氧種(例如超氧 化物或過氧化氫)反應,形成穩定之麩胱苷肽自由基,而變 為二聚物(GSSG:氧化型麩胱苷肽),進而麵胱苷肽還原酶 將來自NADPH之電子轉移至GSSG,而使該二聚物再生為 gsh(還原錢胱苦肽)。麵氧還蛋白(GRX)具有與硫氧化還 原蛋白共用之-Cys-Pro-Tyr-Cys-之活性部位,根據與硫氧化 還原蛋白之共用性而稱為硫氧化還原蛋白超級家族。麩氧 還蛋白存在有在其活性部位之2個半胱胺酸殘基間形成雙 硫鍵之氧化型(s-s)、與還原型(_SH,SH_)。與硫氧化還原 蛋白同樣地,還原型將基質蛋白質之雙硫鍵還原,自身變 153851.doc 201136587 成氧化型。關於其生物活性亦有較多不明之處,但已知其 參與生物體内之氧化還原調節及氧化壓力應答。 如此般,藉由將硫氧化還原蛋白、硫氧化還原蛋白還原 酶、麩胱苷肽還原酶及麩氧還蛋白等氧化還原反應相關因 子活化,或者促進其表現,可減少生物體内過剩之活性氧 種’而防禦生物體免受氧化壓力之影響。 如上所述,本發明者等人此次獲得了以下之驚人見解: 山奈齡及槲皮素將上述氧化還原反應相關因子活化並且促 進其表現。包括山奈酚及槲皮素之黃酮醇類具有以下所示 之通式’該等為廣泛分佈於植物中之類黃酮化合物之一: [化1]
山奈齡:Ri =H ; R2 = H 樹皮素:R| = H 楊梅黃嗣:R2=〇H 已知該等黃酮醇類具有抗氧化作用,另外亦報告有該等黃 酮醇類具有血管強化作用及抗炎症作用。然而,迄今為止 尚未知曉黃酮醇類促進生物體内之氧化還原反應相關因子 之表現,另外,令人極其意外的是於其化學結構極其類似 之忒等黃酮醇類令,僅山奈酚及槲皮素特異性地促進氧化 I53851.doc 201136587 還原反應相關因子之表現。根據上述見解,可明確山奈酚 及槲皮素作為用以促進氧化還原反應相關因子之表現之活 性成分而極其有用。 另外,已周知黃酮醇類可形成各種糖苷,於本發明之氧 化還原反應相關因子表現促進劑中,亦可將山奈酚及槲皮 素之糖苷用作活性成分。於本發明中,與該等形成糖苷之 糖並無限制,作為醛糖,例如可列舉:葡萄糖、甘露糖、 半礼糖、海藻糖、鼠李糖、阿拉伯糖、木糖,作為酮醣, 例如可列舉果糖。 如上所述,山奈酚、槲皮素及該等之糖苷為廣泛分佈於 植物中之成刀,因此含有該等成分之植物萃取物亦對促進 生物體内之氧化還原反應相關因子之表現有用。本發明者 等人發現,於植物萃取物中,尤其是銀杏葉萃取物及山奈 萃取物明顯促進生物體内氧化還原反應相關因子之表現。 因此,於本發明之其他實施態樣中,提供一種含有銀杏葉 萃取物、山奈萃取物或該等之組合作為有效成分而成之氧 化還原反應相關因子表現促進劑。 ;本發月之氧化還原反應相關因子表現促進劑中用作有 效成分的山奈酚、槲皮素或該等之糖苷、或該等之組合之 调配量並無特別限定,為0.00001〜0.5質量%,較佳為 0·0001〜〇.〇01質量%,並且最佳為〇 〇〇〇丨質量〇〇〇5質量 %左右。另外’於本發明之氧化還原反應相關因子表現促 進劑中用作有效成分的銀杏葉萃取物、山奈萃取物或該等 之·纟且合之調配量換算成萃取物乾燥後剩餘部分時,例如為 153851.doc 201136587 0.00001-0.5質量。/〇,較佳為〇.〇〇〇〗〜〇」質量%,並且最佳為 0.0001〜0.01質量%左右。 於本發明中,上述有效成分可作為含有該等之氧化還原 反應相關因子表現促進劑而進行經口或非經口投予,其例 如可製成經口用組合物或外用組合物。另外,藉由本發明 之氧化還原反應相關因子表現促進劑,可維持生物體之健 康,並可防止由氧化壓力引起之各種疾病及症狀。作為此 種疾病及症狀,並無限制,可列舉:癌症;糖尿病;自體 免疫疾病,例如類風濕性關節炎、全身性紅斑狼瘡、抗磷 脂質抗體症候群、皮肌炎、全身性皮膚硬化症、修格蘭氏 症候群(Sjogren's syndrome)、格-巴二氏症候群(Guillain_Barre syndrome) '慢性萎縮性胃炎、主動脈炎症候群、古巴士德 氏症候群(Goodpasture’s syndrome)、急速進行性絲球體腎 炎、巴塞多氏病(Basedow's disease) '慢性盤狀紅斑狼瘡或 為慣性流產;缺血性疾病,例如心絞痛、心肌梗塞、腦梗 塞或阻塞性動脈硬化症;過敏疾病’例如支氣管哮喘、過 敏性鼻炎、花粉症、過敏性胃腸炎、蔞痲疹、接觸性皮炎 或異位性皮炎;皮膚老化;色素沈積;皺紋;脂溢症;曬 傷,燒傷;痤瘡;皮膚鬆弛;肥胖;高血壓;新陳代謝症 候群;貧血。因此,本發明之氧化還原反應相關因子表現 促進劑之用途具有無限之可能性,可以治療目的或美容目 的用作食品、飲料、化妝品、醫藥品、准藥品等之原料及 添加物。 作為經口用組合物可採取之形態,例如除一般食品以 153851.doc 12 201136587 外,可列舉:功能性食品、營養輔助食品、特定保健用食 品、早產兒用調製乳、嬰兒用調製乳、嬰兒用食品、孕產 婦用食tm、老年人用食品、飲料、醫藥品之形態例如亦 可為錠劑、粉末、顆粒、口含錠、内服液、懸浮液、乳濁 液、糖漿等加工形態。 另外本發明之氧化還原反應相關因子表現促進劑除了 本發明之有效成分以外,亦可含有一般飲食品、醫藥品或 准藥品中所使用之各種載體或抗氧化劑等添加物。例如, 本發明之氧化還原反應相關因子之表現促進劑除了本發明 之有效成分以外,亦可作為載體而含有各種承載(carHer) 載體補充劑(extender)、稀釋劑、增量劑、分散劑、賦形 劑、結合劑溶劑(例如水、乙醇、植物油)、溶解助劑、緩衝 劑、溶解促進劑、膠化劑、懸浮劑、麵粉、米粉、澱粉、 玉米殿粉、多糖、乳蛋白質、膠原蛋白、米糠油、卵磷脂。 作為添加劑,例如可列舉:維他命類、甜味劑、有機酸、 著色劑、香料、抗濕劑、纖維、電解質、礦物質、營養素、 抗氧化劑、防腐劑、芳香劑、濕潤劑、天然食物萃取物、蔬 菜萃取物’但並不限定於該等。另外,作為抗氧化劑’例如 可列舉.生育酚類、黃酮衍生物、葉甜素類、曲酸、沒食子 酉文讨生物、兒命素類、蜂鬥酸(fukiic acid)、棉籽盼(gossypol)、 °比呼衍生物、芝麻酚、愈創木醇、愈創木酸、對香豆酸 (eoumaric acid)、去曱二氫愈創酸(nordihydroguaiaretic acid)、 留醇類、萜烯類、核酸鹼基類、類胡蘿菌素類、木聚糖類 之類之天然抗氧化劑,以及抗壞血酸棕櫚酸酯、抗壞血酸 153851.doc -13· 201136587 硬月曰酸酯、丁基羥基苯曱醚(BHA)、丁基羥基甲苯(BHT)、 單-第二丁基對苯二酚(TBHq)、4羥基甲基_2,6_二·第三丁 基苯酚(HMBP)所代表之合成抗氧化劑。 作為外用組合物可採取之形態,例如可製成軟膏、乳劑、 防護劑(protector)、黏附劑、面膜、化妝水、乳液、洗劑、 沐冷劑、洗髮劑、養髮露、整髮液、洗髮精、潤絲精等劑 型,視需要可適當調配作為通常之外用劑而習慣使用之成 为,例如美白劑、保濕劑、油性成分、紫外線吸收劑、界 面活性劑、增黏劑、醇類、粉末成分、著色劑、水性成分、 水、各種皮膚營養劑等。進而,於本發明之氧化還原反應 相關因子表現促進劑中,亦可適當調配外用劑中慣用之助 劑,例如乙二胺四乙酸二鈉、乙二胺四乙酸三鈉、檸檬酸 鈉、聚磷酸鈉、偏磷酸鈉、葡萄糖酸鈉等金屬封阻劑,咖 啡因、單寧、維拉帕米、傳明酸及其衍生物,甘草萃取物、 光甘草啶、木瓜果實之熱水萃取物、各種生藥、生育酚 乙酸酯、甘草酸及其衍生物或其鹽等藥劑,維生素C、抗 壞血酸磷酸鎂、抗壞血酸葡糖苷、熊果苷、曲酸等美白 劑,葡萄糖、果糖、甘露糖、蔗糖、海藻糖等糖類,視 黃酸、視黃醇、視黃醇乙酸酯、視黃醇棕橺酸酯等維生 素A類。 將本發明中投予之氧化還原反應相關因子表現促進劑之 代表配方例表示如下。 I53851.doc 201136587 防腐劑A 組成 十曱基環五矽氧烷 曱基苯基聚矽氧烷 山窬醇 1,3-丁二醇 異硬脂酸聚氧乙烯甘油酯 單硬脂酸聚氧乙稀甘油酉旨 氧化還原反應相關因子表現促進劑: 銀杏葉萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑: 槲皮素 乙二胺四乙酸三鈉 對曱氧基肉桂酸2-乙基己酯 三仙膠 叛基乙烯聚合物 苯氧基乙醇 純化水 香料 防腐劑B 組成 凡士林 二曱基聚矽氧烷 甲基苯基聚矽氧烷 調配量(質量%) 3 3 1 5 1.5 1 0.0001 0.0001 0.1 7 0.1 0.3 適量 剩餘量 適量 調配量(質量%) 1 3 3 153851.doc -15- 201136587 硬脂醇 0.5 甘油 7 二丙二醇 3 1,3-丁二醇 7 木糖醇 3 角鯊烧 1 異硬脂酸 0.5 硬脂酸 0.5 單硬脂酸聚氧乙烯甘油酯 1 單硬脂酸甘油酯 2 氫氧化鉀 0.05 氧化還原反應相關因子表現促進劑: 0.0001 山奈萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑: 0.0001 山奈酚 乙醯化玻尿酸鈉 0.1 EDTA三鈉(乙二胺四乙酸三鈉) 0.05 4-第三丁基-4·-甲氧基二苯甲醯甲烷 2 對曱氧基肉桂酸2-乙基己酯 5 羧基乙烯聚合物 0.1 苯氧基乙醇 適量 純化水 剩餘量 香料 適量 2層型乳劑 153851.doc • 16· 201136587 組成 調配量(質量%) 二曱基聚矽氧烷 5 十甲基環五矽氧烷 25 三曱基矽烷氧基矽酸 5 聚氧乙烯·曱基聚矽氧烷共聚物 2 二丙二醇 5 被覆棕櫚酸糊精之微粒子氧化鋅(60 nm) 15 氧化還原反應相關因子表現促進劑: 0.01 銀杏葉萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑: 0.0005 山奈紛 對羥基苯曱酸酯 適量 苯氧基乙醇 適量 乙二胺四乙酸三鈉 適量 對曱氧基肉桂酸2-乙基己酯 7.5 二曱基二硬脂基銨鋰蒙脫石 0.5 球狀聚丙烯酸烷基酯粉末 5 丁基乙基丙二醇 0.5 純化水 剩餘量 香料 適量 膏 組成 調配量(質量%) 氧化還原反應相關因子表現促進劑: 0.01 銀杏葉萃取液(乾燥後剩餘部分) 153851.doc 17 201136587 氧化還原反應相關因子表現促進劑: 0.001 山奈盼 氧化還原反應相關因子表現促進劑: 0.0001 槲皮素 硬脂醇 18.0 漆樹蠛 20.0 聚氧乙烯(20)單油酸酯 0.25 甘油單硬脂酸酯 0.3 凡士林 40.0 純化水 剩餘量 附劑 組成 調配量(質量%) 氧化還原反應相關因子表現促進劑: 0.0001 山奈萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑: 0.0001 山奈齡 氧化還原反應相關因子表現促進劑: 0.0001 槲皮素 克羅米通 3.2 Panasate 875R 2.5 角鯊烧 1.0 dl-樟腦 0.07 聚氧乙烯(60莫耳)氫化蓖麻油 1.2 濃甘油 5.0 153851.doc -18 · 201136587 明膠 聚乙烯吡咯啶酮Κ-90 對羥苯甲酸曱酯 d-山梨糖醇溶液 氫氧化鋁 脲 亞硫酸鈉 乙二胺四乙酸鈉 檸檬酸
Hiviswako 104R 聚丙烯酸納 羧基甲基纖維素鈉 高嶺土 純化水 離子導入劑 組成 氧化還原反應相關因子表現促進劑: 銀杏葉萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑·· 山奈萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑: 山奈酚 氧化還原反應相關因子表現促進劑: 槲皮素 1.2 0.6 適量 35.0 0.2 1.3 適量 適量 適量 0.22 0.24 2.8 1.0 剩餘量 調配量(質量%) 0.0001 0.0001 0.0001 0.0001 15385 丨.doc -19- 201136587 甘油 1,3-丁二醇 玻尿酸 檸檬酸(食品) 離子交換水 糖果A 組成 氧化還原反應相關因子表現促進劑: 銀杏葉萃取液(乾燥後剩餘部分) 砂糖 飴糖 香料 錠劑C 組成 氧化還原反應相關因子表現促進劑: 山奈萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑: 槲皮素 蔗糖酯 甲基纖維素 甘油
N-乙醯葡糖胺 玻尿酸 維生素E 5.0 5.0 0.05 0.35 剩餘量 調配量(質量%) 0.5 50.000 剩餘量 1.000 調配量(質量%) 0.1 0.5 4.667 2.400 1.667 24.7998 20.000 12.000 153851.doc -20- 201136587 維生素Β6 1.333 維生素Β2 0.667 (X-類脂酸 1.333 輔酶Q10 2.667 腦醯胺(筠篛萃取物) 3.333 L-脯胺酸 20.000 結晶纖維素 軟膠囊Β 剩餘量 組成 調配量(質量%) 氧化還原反應相關因子表現促進劑: 銀杏葉萃取液(乾燥後剩餘部分) 0.1 氧化還原反應相關因子表現促進劑: 山奈酚 0.001 氧化還原反應相關因子表現促進劑: 槲皮素 0.0001 食用大豆油 35.333 蜂王漿 16.4668 瑪卡 2.000 GABA(y-amino butyric acid,γ-胺基 丁酸) 2.000 蜂蠟 4.000 明膠 剩餘量 甘油 8.000 甘油脂肪酸酯 顆粒Α-Β 7.000 153851.doc -21 · 201136587 組成 氧化還原反應相關因子表現促進劑: 銀杏葉萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑: 山奈萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑: 山奈盼 大豆異黃酮 還原乳糖 大豆寡糖 赤藻糖醇 糊精 檸檬酸 香料 飲料A 組成 氧化還原反應相關因子表現促進劑: 銀杏葉萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑: 山奈萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑: 山奈盼 氧化還原反應相關因子表現促進劑: 槲皮素 調配量(質量°/〇) 0.01 0.02 0.001 42.2998 45.000 3.000 3.000 2.500 2.000 剩餘量 調配量(質量%) 0.001 0.001 0.0001 0.0001 153851.doc -22- 201136587 還原麥芽糖飴糖 赤藻糖醇 檸檬酸 香料 N-乙醯葡糖胺 玻尿酸 維生素E 維生素B6 維生素B2 α-類脂酸 輔酶Q10 腦醯胺(药篛萃取物) L-脯胺酸 純化水 曲奇 組成 氧化還原反應相關因子表現促進劑: 銀杏葉萃取液(乾燥後剩餘部分) 氧化還原反應相關因子表現促進劑: 山奈紛 低筋麵粉 奶油 微晶砂糖 雞蛋 65.3998 16.000 4.000 2.600 2.000 1.000 0.600 0.400 0.200 0.400 2.400 0.800 4.000 剩餘量 調配量(質量%) 0.5 0.5 48.7998 17.500 20.000 12.500 153851.doc -23- 201136587 剩餘量 香料 一面攪拌奶油一面緩緩添加微晶砂糖後,添加雞蛋、銀 杏葉萃取液、山奈萃取液、山奈盼、槲皮素及香料並進一 步攪拌。充分混合後,添加經均勻振盪之低筋麵粉,低速 攪拌,以塊狀置於冰箱中。其後,進行成型並於170°C下焙 烤15分鐘而形成曲奇。 [實施例] 例1.促進硫氧化還原蛋白系之表現之藥劑之探索 於高濕、5% C02、37t之條件下,於限制性角質細胞 (Defined Keratinocyte)-SFM 培養基(10744-019,GIBCO)中 培養正常人表皮角質細胞(KK-4〇09,KURABO)。將最終密 度為100%之細胞置換至鈣濃度調整為1.5 mM之EpiLifeTM 無妈無酴紅(CalciuM-Free Phenol Red Free)培養基 (M-EPICF/PRF-5 00,KURABO)中。24小日夺後,以最終濃度 成為10 μΜ之方式於該等之中添加山奈酚(K0018,東京化成 工業股份有限公司)、維生素E(95240,FULKA)及類脂酸 ((+/-)_α-類脂酸)(T1395,SIGMA)。 藥劑添加後,於24小時後使用QIAZOL溶胞試劑(Lysis Reagent)(79306,QIAGEN)離析 RNA,並使用 RNeasy套組 (74106, QIAGEN)將 RNA 純化。其後,使用 QuantiTect SYBR Green RT-PCR套組(204243,QIAGEN),藉由 LightCycler軟 體(Roche) ’對硫氧化還原蛋白還原酶、硫氧化還原蛋白、 麩胱苷肽還原酶、麩氧還蛋白、以及作為内部標準之核糖 體蛋白(ribosomal protein)之mRNA量進行定量。所使用之 153851.doc -24· 201136587 引子之序列如下所示。 硫氧化還原蛋白還原酶•前置引子: TGCTGGCAATAGGAAGAGATGGCTTGCAC 硫氧化還原蛋白還原酶•反置引子: GCAATCTTCCTGCCTGCCTGGATTGCAACTGG 硫氧化還原蛋白•前置引子: TCGGTCCTTACAGCCGCTCGTCAGACTCCA 硫氧化還原蛋白•反置引子: AGGCCCACACCACGTGGCTGAGAAGTCAAC 麩胱苷肽還原酶•前置引子: GATCCTGTCAGCCCTGGGTTCTAAGACATC 麩胱苷肽還原酶•反置引子: TAACCATGCTGACTTCCAAGCCCGACAA 麩氧還蛋白•前置引子: ATCACAGCCACCAACCACACTAACGAGA 麩氧還蛋白•反置引子: GTTACTGCAGAGCTCCAATCTGCTTTAGCC 核糖體蛋白•前置引子: ACAGAGGAAACTCTGCATTCTCGCTTCCTG 核糖體蛋白•反置引子: CACAGACAAGGCCAGGACTCGTTTGTACC 將硫氧化還原蛋白還原酶、硫氧化還原蛋白、麩胱苷肽 還原酶及麩氧還蛋白之mRNA量除以核糖體蛋白之mRNA 量所得者作為mRNA表現量。 153851.doc •25- 201136587 其結果,與已知具有抗氧化作用之維生素E及類脂酸相 比,山奈酚明顯促進氧化還原反應相關因子之表現(圖丨)。 例2.山奈酚對皮膚等價模型中之氧化還原反應相關因子 表現之作用 由正常人、正常人角質細胞(Invitr〇gen)、正常人纖維母 細胞(ATCC)及膠原蛋白I(Sigma)製作皮膚等價模型,並且 於高濕' 5°/。C〇2、37度之條件下,將其培養於達爾伯克氏 改良伊格爾(Dulbecco's Modified Eagle's)培養基(D-MEM) (Invitrogen)中。向該培養基中添加2 mM或10 mM之山奈 酚’並將該模型培養24小時。其後,使用QiAGEN mRNA 離析套組’自皮膚等價模型之上皮層離析RNA。繼而,藉 由使用即時(Real-time)PCR套組(Bio-Rad)之q-PCR(利用 Bio-Rad MyiQ單色即時PCR檢測系統之定量PCR),對硫氧 化還原蛋白還原酶及麩胱苷肽還原酶、以及作為内部標準 之36B4之mRNA進行定量。引子購買自qIAGeN(TXNRD2 : #QT00070371 ; GSR ; #QT00038325)。將硫氧化還原蛋白 還原酶量及麩胱苷肽還原酶量除以3 6B4之mRNA量,獲得 mRNA表現水平。 其結果,山奈酚明顯促進皮膚等價模型中之氧化還原反 應相關因子之表現(圖2)。 例3.促進硫氧化還原蛋白系之表現之藥劑之探索-類黃酮 化合物 於高濕、5% C〇2、37度之條件下,於限制性角質細胞_SFM 培養基(10744-019,GIBCO)中培養正常人表皮角質細胞 I53851.doc -26- 201136587 (KK-4009, KURABO)。將最終密度為100%之細胞置換至鈣 濃度調整為1.5 mM之EpiLifeTM無鈣無酚紅培養基 (M-EPICF/PRF-500,KURABO)中。24小時後,以最終濃度 成為1 0 μΜ之方式添加下述藥劑。 • 山奈酚(Κ0018,東京化成工業股份有限公司) : 槲皮素(173-00403,和光純藥工業股份有限公司) • 楊梅黃酮(70050,FLUKA) 表沒食子兒茶素沒食子酸酯(Ε4143,CIAL) 橙皮甘(086-07342,和光純藥工業股份有限公司) 芹菜素(012-1 8913,和光純藥工業股份有限公司) 染料木黃酮(genistein)(070-04681,和光純藥工業股份有 限公司) 藥劑添加後,於24小時後藉由上述例1之方法對氧化還原 反應相關因子之mRNA之表現量進行定量。 其結果,上述類黃酮化合物中,僅山奈酚與槲皮素明顯 促進硫氧化還原蛋白系之表現(圖3)。 例4.促進硫氧化還原蛋白系之表現之藥劑之探索-植物萃 取物之探索
• 於高濕、5% C02、37度之條件下,於限制性角質細胞-SFM . 培養基(10744-019,GIBCO)中培養正常人表皮角質細胞 (KK-4009,KURABO)。將最終密度為100%之細胞置換至鈣 濃度調整為1.5 mM之EpiLifeTM無鈣無酚紅培養基 (M-EPICF/PRF-500,KURABO)中。24小時後,以最終濃度 成為0.1%之方式添加下述藥劑: 153851.doc -27- 201136587 山奈萃取液:藉由50%之1>3_丁二醇對山奈(Kaempferia galanga)之根莖進行萃取而獲得者; 銀杏葉萃取液.將銀杏(Ginkgo biloba L.)葉之50%乙醇萃 取物轉溶於1,3-丁二醇中而獲得者; 甜茶萃取物.將甜茶(Rubus Suavissimus shugan Lee.(Rosaseae))之熱水萃取物轉溶於5〇%之1>3 丁二醇中而 獲得者。 藥劑添加後’於24小時後藉由例1之方法對氧化還原反應 相關因子之mRNA之表現量進行定量。 其結果,可確認於已知含有山奈酚、槲皮素及該等之糖 苦之植物萃取液中,銀杏葉萃取液或山奈萃取液尤其促進 硫氧化還原蛋白系之表現(圖4)。 例5 ·硫氧化還原蛋白還原酶活性促進效果 於高濕、5。/〇 C〇2、37度之條件下,於限制性角質細胞_SFM 培養基(10744-019,GIBCO)中培養正常人表皮角質細胞 (KK-4009, KURABO)。將最終密度為100%之細胞置換至約 濃度調整為1.5 mM之EpiLifeTM無鈣無酚紅培養基 (M-EPICF/PRF-500,KURAB0)中。24小時後,以最終濃度 成為10 μΜ之方式添加山奈酚(K0018,東京化成工業股份有 限公司)或槲皮素(173-00403,和光純藥工業股份有限公 司)°藥劑添加後,於24小時後使其溶解於溶解緩衝劑中, 藉由15分鐘、4°C之離心分離操作,以14,000 rpm之轉速將 不溶性組分去除。對可溶性組分中之總蛋白質量進行定量 後’依據Arne Holmgren等人之硫氧化還原蛋白還原酶活性 15385l.doc -28- 201136587 測定方法(METHODS IN ENZYMOLOGY,1995, 252, 199-) 進行活性測定。 其結果,可確認山奈酚及槲皮素促進硫氧化還原蛋白還 原酶之活性(圖5)。 例6.山奈盼、山奈萃取液、銀杏葉萃取液對炎症性細胞激 素(IL1 β)之表現之抑制效果 於高濕、5% C02、37度之條件下,於限制性角質細胞-SFM 培養基(10744-019,GIBCO)中培養正常人表皮角質細胞 (KK-4009, KURABO)。將最終密度為100%之細胞置換至辦 濃度調整為1·5 mM之EpiLifeTM無鈣無酚紅培養基 (M-EPICF/PRF-500,KURABO)中。24小時後,以最終濃度 成為10 μΜ之方式添加山奈酚,以最終濃度成為0.1%之方式 添加下述植物萃取液: 山奈酚(Κ00 1 8,東京化成工業股份有限公司); 山奈萃取液:藉由50%之1,3-丁二醇對山奈(Kaempferia galanga)之根莖進行萃取而獲得者; 銀杏葉萃取液:將銀杏(Ginkgo biloba L.)葉之50%乙醇萃 取物轉溶於1,3-丁二醇中而獲得者。 藥劑添加後,於24小時後藉由例1之方法萃取RNA,對炎 症相關因子(ILlp)之mRNA表現量進行定量。所使用之引子 如下所述。 ILip ·前置引子: GGCCATGGACAAGCTGAGGAAGAT.GCTG IL1P ·反置引子: 153851.doc -29· 201136587
TGCATCGTGCACATAAGCCTCGTTATCCC 將Ιίΐβ之mRNA量除以核糖體蛋白之mRNA量而獲得者 作為mRNA表現量。 其結果,由於轉由山奈盼、山奈举取液及銀杏葉萃取液 可抑制炎症性細胞激素即IL1P之產生,因此可確認該等成 分具有抗炎症作用(圖6)。 【圖式簡單說明】 圖1係表示山奈酚促進生物體内之氧化還原反應表現因 子之表現的圖; 圖2係表示山奈酚促進皮膚等價模型中之氧化還原反應 相關因子之表現的圖; 圖3係表示類黃酮化合物對硫氧化還原蛋白系之表現之 促進作用中的比較之圖; 圖4係表示銀杏葉萃取液及山奈萃取液促進硫氧化還原 蛋白還原酶之表現的圖; 圖5係表示山奈酚及槲皮素對硫氧化還原蛋白還原酶之 活性促進效果的圖;及 圖6係表示山奈酚、銀杏葉萃取液及山奈萃取液抑制炎症 性細胞激素(ILip)之產生之效果的圖。 153851 .doc •30· 201136587 序 列表 <110>日商資生堂股份有限公司 <120>氧化還原反應相關因子表現促進劑
<130> Y826-PCT <140> 100103496 <141> 2011-01-28 <150> 61/299,589 <151> 2010-01-29 <160〉 12 〈170> Patentln 第 3.1 版 <210〉 1 <211> 29 <212> DNA <213〉 Artificial <220〉 29 <223〉 forward primer <400〉 1 tgctggcaat aggaagagat ggcttgcac <210> <211〉 〈212〉 <213> 2 32 DNA 人工的 <223> 前置引子 <400> 2 gcaatcttcc tgcctgcctg gattgcaact gg 32 <210〉 <211〉 <212〉 <213> 3 30 DNA 人工的 <220〉 <223>前置引子 <400〉 3 tcggtcctta cagccgctcg tcagactcca 30 <210〉<211> <212〉 <213〉 4 30 DNA 人工的 <220〉 <223〉 反置引子 <400〉 4 aggcccacac cacgtggctg agaagtcaac 30 <210〉<211><212〉 <213> 5 30 DNA 人工的 <220〉 <223〉前置引子 <400〉 5 gatcctgtca gccctgggtt ctaagacatc <210〉 6 <211〉 28 <212〉 DNA <213〉 人工的<220〉 <223〉 反置引子 153851-序列表.doc 30 201136587 <400> 6 taaccatgct gacttccaag cccgacaa 28 <210〉 7
<211〉 28 <212〉 DNA <213> 人工的 <220〉 <223〉前置引子 <400> 7 atcacagcca ccaaccacac taacgaga 28 <210〉 8 <211〉 30 <212> DNA <213〉 人工的 <220〉 <223> 反置引子 <400> 8 gttactgcag agctccaatc tgctttagcc 30 〈210〉 9 <211> 30 <212〉 DNA <213> 人工的 <220〉 <223〉 前置引子 <400〉 9 acagaggaaa ctctgcattc tcgcttcctg 30 <210〉 10 <211〉 29 <212〉 DNA <213〉 人工的 <220〉 <223〉 反置引子 <400〉 10 cacagacaag gccaggactc gtttgtacc 29 <210> 11 <211> 28 <212> DNA <213> 人工的 <220〉 <223> 前置引子 <400> 11 ggccatggac aagctgagga agatgctg 28 <210> 12 <211〉 29 <212〉 DNA <213〉 人工的 <220〉 <223〉 反置引子 <400> 12 tgcatcgtgc acataagcct cgttatccc 29 153851-序列表.doc
Claims (1)
- 201136587 七、申請專利範圍: 1 · 種氧化還原反應相關因子表現促進劑,其係含有山奈 齡、槲皮素或該等之糖苷、或該等之組合作為有效成分 而成。 . 2·如清求項1之氧化還原反應相關因子表現促進劑,其中上 . 述氧化還原反應相關因子為選自由硫氧化還原蛋白、硫 _ 氧化還原蛋白還原酶、麩胱苷肽還原酶及麩氧還蛋白所 組成之群中之1種或複數種物質。 3. 種氧化還原反應相關因子表現促進劑,其係含有銀杏 葉萃取物、山奈萃取物或該等之組合作為有效成分而成。 4. 如請求項3之氧化還原反應相關因子表現促進劑,其中上 述氧化還原反應相關因子為選自由硫氧化還原蛋白、硫 氧化還原蛋白還原酶、麩胱苷肽還原酶及麩氧還蛋白所 組成之群中之1種或複數種物質。 I53851.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29958910P | 2010-01-29 | 2010-01-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201136587A true TW201136587A (en) | 2011-11-01 |
TWI572353B TWI572353B (zh) | 2017-03-01 |
Family
ID=44319447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW100103496A TWI572353B (zh) | 2010-01-29 | 2011-01-28 | 氧化還原反應相關因子表現促進劑 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20110189318A1 (zh) |
EP (1) | EP2529736A4 (zh) |
JP (1) | JP5833438B2 (zh) |
KR (1) | KR20120119976A (zh) |
CN (1) | CN102361637A (zh) |
BR (1) | BRPI1100012A2 (zh) |
RU (1) | RU2606856C2 (zh) |
TW (1) | TWI572353B (zh) |
WO (1) | WO2011093469A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU91412B1 (en) * | 2008-01-30 | 2009-07-31 | Wurth Paul Sa | Charging device for distributing bulk material |
JP2016006021A (ja) * | 2014-06-20 | 2016-01-14 | 株式会社ノエビア | チオレドキシン関連因子発現促進剤 |
JP2016088905A (ja) * | 2014-11-07 | 2016-05-23 | 健治 椛島 | 上皮又は粘膜に投与される組成物 |
WO2016132483A1 (ja) * | 2015-02-18 | 2016-08-25 | 学校法人福岡大学 | ヒトキマーゼ阻害剤及びヒトキマーゼの活性が関与する疾患の予防治療用薬剤 |
JPWO2022075096A1 (zh) * | 2020-10-07 | 2022-04-14 | ||
JP6860739B1 (ja) * | 2020-11-20 | 2021-04-21 | ジェイ−ネットワーク,インコーポレイテッド | 表皮内の抗酸化物質の発現増強剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0769862A (ja) * | 1993-09-01 | 1995-03-14 | Kao Corp | 入浴剤組成物 |
JP3578858B2 (ja) | 1995-12-11 | 2004-10-20 | 株式会社ノエビア | 皮膚外用剤 |
US6471972B1 (en) * | 1996-11-07 | 2002-10-29 | Lvmh Recherche | Cosmetic treatment method for fighting against skin ageing effects |
US20040043047A1 (en) * | 1999-03-26 | 2004-03-04 | Parfums Christian Dior | Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of the CD44 membrane receptors of skin cells |
US20040101578A1 (en) * | 2001-08-03 | 2004-05-27 | Min-Young Kim | Compositon containg ginkgo biloba that inhibit angiogenesis and matrix metalloprotinase |
CA2540725A1 (en) * | 2003-11-05 | 2005-05-26 | Osteoscreen, Inc. | Stimulation of hair growth by ginkgo biloba flavonoids |
WO2006033351A1 (ja) | 2004-09-22 | 2006-03-30 | Kyoto University | チオレドキシン発現誘導用組成物 |
KR20060080376A (ko) * | 2005-01-05 | 2006-07-10 | 하수용 | 무기 광물 용해액 및 식물 추출물을 포함하는 화장료조성물 및 그의 제조 방법 |
US20060165812A1 (en) * | 2005-01-21 | 2006-07-27 | Amershire Investment Corporation | Method and topical formulation for treating headaches |
KR100665966B1 (ko) * | 2005-09-23 | 2007-01-09 | 장정만 | 규산염과 은행잎추출물로 제조되는 입욕제의 조성물 및제조제법 |
JP2007284430A (ja) | 2006-03-20 | 2007-11-01 | Rohto Pharmaceut Co Ltd | グルタチオン産生促進剤 |
JP2007269671A (ja) | 2006-03-30 | 2007-10-18 | Redox Bioscience Inc | アレルギー性皮膚炎の予防ないし治療剤 |
JP2009132662A (ja) * | 2007-11-30 | 2009-06-18 | Maruzen Pharmaceut Co Ltd | グルタチオン産生促進剤 |
-
2010
- 2010-12-28 US US12/980,051 patent/US20110189318A1/en not_active Abandoned
-
2011
- 2011-01-28 JP JP2011507745A patent/JP5833438B2/ja active Active
- 2011-01-28 EP EP11737179.9A patent/EP2529736A4/en not_active Withdrawn
- 2011-01-28 TW TW100103496A patent/TWI572353B/zh active
- 2011-01-28 CN CN2011800001278A patent/CN102361637A/zh active Pending
- 2011-01-28 BR BRPI1100012A patent/BRPI1100012A2/pt not_active IP Right Cessation
- 2011-01-28 WO PCT/JP2011/051811 patent/WO2011093469A1/ja active Application Filing
- 2011-01-28 KR KR1020117006205A patent/KR20120119976A/ko not_active Application Discontinuation
- 2011-01-28 RU RU2011134486A patent/RU2606856C2/ru not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2011093469A1 (ja) | 2011-08-04 |
RU2011134486A (ru) | 2013-02-27 |
TWI572353B (zh) | 2017-03-01 |
JP5833438B2 (ja) | 2015-12-16 |
US20110189318A1 (en) | 2011-08-04 |
BRPI1100012A2 (pt) | 2016-05-03 |
RU2606856C2 (ru) | 2017-01-10 |
EP2529736A1 (en) | 2012-12-05 |
CN102361637A (zh) | 2012-02-22 |
JPWO2011093469A1 (ja) | 2013-06-06 |
EP2529736A4 (en) | 2013-07-10 |
KR20120119976A (ko) | 2012-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5361820B2 (ja) | グルタチオン増強用組成物 | |
TW201136587A (en) | An agent for enhancing the expression of redox-associated factors | |
FR2969495A1 (fr) | Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant | |
US20160271028A1 (en) | Novel use of panduratin derivatives or extract of kaempferia pandurata comprising the same | |
JP6563175B2 (ja) | Vegf産生促進剤、育毛及び/又は発毛促進剤 | |
KR20130103945A (ko) | 플라본 화합물의 15-하이드록시프로스타글란딘 탈수소효소 활성의 억제 효능 및 그의 용도 | |
JP5403942B2 (ja) | グルタチオン産生促進剤およびグルタチオンの欠乏に起因する疾患の予防・治療剤 | |
JPWO2007011066A1 (ja) | 繊維芽細胞賦活剤、コラーゲン産生促進剤、コラーゲン収縮促進剤、ヒアルロン酸産生促進剤、atp産生促進剤、メラニン生成抑制剤、皮膚外用剤 | |
JP5773111B2 (ja) | 皮膚の色素沈着を抑制する組成物およびその利用 | |
WO2017018336A1 (ja) | 抗炎症剤 | |
JP6096964B2 (ja) | セラミド合成促進用飲食品 | |
KR101483872B1 (ko) | 신갈나무 잎 분획물을 포함하는 항주름용 조성물 | |
WO2014171333A1 (ja) | ミトコンドリア活性化剤 | |
JP2011207815A (ja) | 抗酸化ストレス剤 | |
JP2017052750A (ja) | 新規エラジタンニンおよび口腔用剤 | |
JP5885902B2 (ja) | デヒドロアスコルビン酸レダクターゼ活性促進剤並びに該促進剤を含有する組成物 | |
JP2012171909A (ja) | 糖化阻害剤 | |
JP2006273756A (ja) | セラミド合成促進剤、コラゲナーゼ阻害剤及びコラーゲン合成促進剤 | |
JP6375100B2 (ja) | 抗老化剤、美白剤、皮膚化粧料および飲食品 | |
JP7301347B2 (ja) | サーチュイン1活性化剤及びサーチュイン1活性化用皮膚化粧料 | |
EP3932386A1 (en) | Combination and use of red propolis and red algae | |
JP2023184311A (ja) | Nqo1発現促進剤 | |
KR20150111793A (ko) | 펄첼라민 g을 유효성분으로 포함하는 항염증제 | |
JP2022098492A (ja) | 脳内のミトコンドリア生合成能向上用組成物 | |
KR20220121930A (ko) | 무궁화 복합추출물을 유효성분으로 포함하는 항염증, 피부 보습, 피부 가려움증 개선, 및 피부재생 촉진용 조성물 |